Fluconazole Capsules

1. Pharmacology: This product belongs to the azole antifungal drug with a broad antifungal spectrum. It can be taken orally or intravenously. This product is effective against fungal infections in humans and various animals, such as Candida infections (including systemic candidiasis in humans and animals with normal or impaired immunity), Cryptococcus neoformans infections (including intracranial infections), Malassezia furfur, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis (including intracranial infections), and Histoplasma capsulatum. The in vitro antibacterial activity of this product is significantly lower than that of ketoconazole, but the in vivo antibacterial activity of this product is significantly higher than that of the in vitro effect. The mechanism of action of this product is mainly to highly selectively interfere with the activity of fungal cytochrome P-450, thereby inhibiting the biosynthesis of ergosterol on the fungal cell membrane. 2. Toxicology: This product is highly selective for the cytochrome P-450 enzyme that fungi depend on. Taking 0.5g of this product once a day for 28 consecutive days has been shown to have no effect on the plasma testosterone concentration in men and the steroid hormone concentration in women of childbearing age.

The main ingredient of this product is fluconazole

The content of this product is white or off-white powder.

This product is mainly used for patients with more severe conditions in the following indications: 1. Candidiasis: used to treat oropharyngeal and esophageal Candida infections; disseminated Candidiasis includes peritonitis, pneumonia, urinary tract infections, etc.; Candida vulvovaginitis can also be used to prevent the occurrence of Candida infections in bone marrow transplant patients receiving cytotoxic drugs or radiotherapy 2. Cryptococcosis: can be used to treat new cryptococcosis other than meninges; when treating cryptococcal meningitis, this product can be used as a maintenance therapy after the initial treatment with amphotericin B combined with flucytosine 3. Coccidioidomycosis 4. This product can also replace itraconazole for the treatment of blastomycosis and histoplasmosis

Oral administration: 100mg to 200mg at a time, 1 to 2 times a day

1 Common gastrointestinal reactions include nausea, vomiting, abdominal pain or diarrhea. 2 Allergic reactions: may manifest as rash, occasionally severe exfoliative dermatitis (often accompanied by liver damage), exudative erythema multiforme. 3 Hepatotoxicity: mild transient elevation of serum aminotransferase may occur during treatment, and hepatotoxic symptoms may occasionally occur, especially in patients with serious underlying diseases (such as AIDS and cancer). 4 Dizziness and headache may be seen. 5 Some patients, especially those with serious underlying diseases (such as AIDS and cancer), may have abnormal renal function. 6 Transient changes in peripheral blood test indicators such as neutropenia and thrombocytopenia may occasionally occur, especially in patients with serious underlying diseases (such as AIDS and cancer).

Patients with a history of allergy to this product or other azole drugs are contraindicated

Precautions for children: There is a lack of sufficient research data on the effects of this product on children. Although a small number of pediatric patients aged 2 weeks to 14 years old have not experienced adverse reactions when treated with a daily dose of 3-6 mg/kg (by body weight), it is still not suitable for children. Precautions for pregnancy and lactation: 1. In animal experiments, when this product is given to animals at high doses, miscarriage, increased stillbirths, rib deformities in young animals, cleft palate and other changes may occur. Although such conditions have not been found in humans, pregnant women should still not use it. 2. There is no data on the concentration of this product in breast milk, so lactating women should use it with caution or stop breastfeeding when taking this product. Precautions for the elderly: Elderly patients with no renal function impairment do not need to adjust the dose. Elderly patients with renal impairment should adjust the dose according to creatinine clearance (see [Usage and Dosage] for details).

1. When this product is used in combination with isoniazid or rifampicin, the concentration of this product may be reduced. 2. When this product is used in combination with sulfonylurea hypoglycemic drugs such as tolbutamide, chlorbutamide and glipizide, the blood concentration of these drugs may increase, which may lead to hypoglycemia. Therefore, blood sugar should be monitored and the dose of sulfonylurea hypoglycemic drugs should be reduced. 3. When this product is used in combination with cyclosporine, the blood concentration of cyclosporine may increase, which increases the risk of toxic reactions. Therefore, it must be used with caution while monitoring the blood concentration of cyclosporine and adjusting the dose. Use with caution 4. This product can increase the blood concentration of this product when used in combination with hydrochlorothiazide 5. When used in combination with theophylline, the blood concentration of theophylline can increase by about 13%, which can lead to toxic reactions, so the blood concentration of theophylline needs to be monitored 6. This product can enhance the anticoagulant effect of the coumarin anticoagulants such as warfarin, resulting in a prolonged prothrombin time, so the prothrombin time should be monitored and used with caution 7. This product can increase the blood concentration of phenytoin sodium when used in combination with phenytoin sodium, so the blood concentration of phenytoin sodium needs to be monitored

Keep tightly closed in a dry place.

0.15 g

SPH Zhongxi Pharmaceutical Co., Ltd.

• Founded in:

  1989-10-18

• Address:

  No. 446, Waiqingsong Road, Jiading District, Shanghai

• Tax NO.:

  9131011413362209XY

• Registered Funds:

  148.2 million yuan

• Email:

  Log in to view